AI brief of an SEC Form 8-K · Erie Indemnity (ERIE)

Erie Indemnity Q2 net income rises to $180.3 million, or $3.45 per diluted share

Positive Impact 3 of 5 earnings Written later

Erie Indemnity reported second-quarter 2026 net income of $180.3 million, or $3.45 per diluted share, up from $174.7 million, or $3.34 per diluted share, a year earlier. Operating income before taxes rose $5.0 million, or 2.5 percent, and first-half net income also increased. The board also approved a quarterly Class A dividend of $1.4625 per share, payable October 20, 2026, compared with $1.365 per share declared in the second quarter of 2025.

Key points

  • Q2 2026 net income was $180.3 million, or $3.45 per diluted share, versus $174.7 million, or $3.34, in Q2 2025.
  • First-half 2026 net income was $330.8 million, or $6.32 per diluted share, versus $313.1 million, or $5.99, in the first half of 2025.
  • Operating income before taxes rose 2.5 percent in Q2 2026, with management fee revenue for policy issuance and renewal services up $39.0 million, or 4.7 percent.
  • Dividend No. 385 of $1.4625 per Class A share has a record date of October 5, 2026 and a payable date of October 20, 2026.

The filing

CompanyErie Indemnity (ERIE)
Form8-K, current report
Filed with the SECJul 30, 2026, 4:20 PM ET
Accession number0001628280-26-051071

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:07 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.